Pharmacotherapy of obsessive-compulsive disorder: Evidence-based treatment and beyond

Australian and New Zealand Journal of Psychiatry

Volumn 47, Issue 2, 2013, Pages 121-141

  Fineberg, Naomi A ^a   Reghunandanan, Samar ^a   Brown, Angus ^a   Pampaloni, Ilenia ^b  

^a QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^b SURREY AND BORDERS PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Clinical trials; meta analysis; obsessive compulsive disorder; randomised control; systematic reviews

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MIRTAZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGITATION; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; CLOMIPRAMINE; EVIDENCE-BASED MEDICINE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; RECURRENCE; SEROTONIN UPTAKE INHIBITORS;

EID: 84873647899     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867412461958     Document Type: Review

References (195)

1. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Journal of Clinical Psychopharmacology. 2009 ; 29: 51-55
2. Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive compulsive disorder: A quantitative review. Journal of Consulting and Clinical Psychology. 1997 ; 65: 44-52 (Pubitemid 27086134)
3. Aizenberg D, Naor S, Zemishlany Z, et al. The serotonin antagonist mianserin for treatment of serotonin-reuptake inhibitor-induced sexual dysfunction: An open-label study. Clinical Neuropharmacology. 1999 ; 22: 347-350
4. Albert U, Aguglia E, Maina G, et al. Venlafaxine versus clomipramine in the treatment of obsessive compulsive disorder: A preliminary, single-blind 12-week controlled study. Journal of Clinical Psychiatry. 2002 ; 63: 1004-1009 (Pubitemid 35388059)
5. Amiaz R, Fostick L, Gershon A, et al. Naltrexone augmentation in OCD: A double-blind placebo-controlled cross-over study. European Neuropsychopharmacology. 2008 ; 18: 455-461
6. Ananth J, Pecknold JC, Van Den Steen N, et al. Double-blind comparative study of clomipramine and amitriptyline in obsessional neurosis. Progress in Neuropsychopharmacology. 1981 ; 5: 257-262 (Pubitemid 11012289)
7. Angst J, Gamma A, Endrass J, et al. Obsessive-compulsive severity spectrum in the community: Prevalence, co morbidity and course. European Archives of Psychiatry and Clinical Neuroscience. 2004 ; 254: 156-164 (Pubitemid 39304465)
8. Baldwin SD, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology. 2005 ; 19: 567-596 (Pubitemid 41578819)
9. Barr LC, Goodman WK, Anand A, et al. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. American Journal of Psychiatry. 1997 ; 154: 1293-1295 (Pubitemid 27369184)
10. Bejerot S, Bodlund O. Response to high doses of citalopram in treatment-resistant obsessive compulsive disorder. Acta Psychopharmacologica Scandinavica. 1998 ; 98: 423-424 (Pubitemid 28529688)
11. Bergeron R, Ravindran AV, Chaput Y, et al. Sertraline and fluoxetine treatment of obsessive compulsive disorder: Results of a double-blind, 6-month treatment study. Journal of Clinical Psychopharmacology. 2001 ; 22: 148-154 (Pubitemid 34289389)
12. Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry. 2010 ; 72: 716-721
13. Bisserbe JC, Lane RM, Flament MF. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. European Psychiatry. 1997 ; 12: 82-93 (Pubitemid 27130193)
14. Blier P, Bergeron R. Sequential administration of augmentation strategies in treatment resistant obsessive compulsive disorder: Preliminary findings. International Clinical Psychopharmacology. 1996 ; 11: 37-44 (Pubitemid 26135299)
15. Bloch MH, McGuire J, Landeros-Weisenberger A, et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry. 2010 ; 15: 850-855
16. Bogetto F, Albert U, Maina G. Sertraline treatment of obsessive-compulsive disorder: Efficacy and tolerability of a rapid titration regimen. European Neuropsychopharmacology. 2002 ; 12: 181-186 (Pubitemid 34462210)
17. Byerly MJ, Goodman WK, Christenen R. High doses of sertraline for treatment-resistant obsessive compulsive disorder. American Journal of Psychiatry. 1996 ; 153: 1232-1233 (Pubitemid 26299850)
18. Bystritsky A, Ackerman DL, Rosen RM, et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: A placebo-controlled trial. Journal of Clinical Psychiatry. 2004 ; 65: 565-568
19. Carey PD, Vythilingum B, Seedat S, et al. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: A double-blind, randomised, placebo-controlled study. Biomed Central Psychiatry. 2005 ; 5: 5
20. Clomipramine in the treatment of patients with obsessive compulsive disorder. Archives of General Psychiatry. 1991 ; 48: 730-738
21. Connor KM, Payne VM, Gadde KM, et al. The use of aripiprazole in obsessive-compulsive disorder: Preliminary observations in 8 patients. Journal of Clinical Psychiatry. 2005 ; 66: 49-51
22. Coric V, Sarper T, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open label trial. Biological Psychiatry. 2005 ; 58: 424-428 (Pubitemid 41219711)
23. Cottraux J, Mollard E, Bouvard M, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. International Clinical Psychopharmacology. 1990 ; 5: 17-30
24. Dannon PN, Sasson Y, Hirschmann S, et al. Pindolol augmentation in treatment resistant obsessive compulsive disorder. A double-blind placebo-controlled trial. European Neuropsychopharmacology. 2000 ; 10: 165-169 (Pubitemid 30227616)
25. Denys D, De Geus F, Van Megen HJ, et al. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. Journal of Clinical Psychiatry. 2004 ; 65: 1040-1048
26. Denys D, Fineberg N, Carey PD, et al. Quetiapine addition in obsessive-compulsive disorder: Is treatment outcome affected by type and dose of serotonin reuptake inhibitors?. Biological Psychiatry. 2007 ; 61: 412-414 (Pubitemid 46108696)
27. Denys D, Van Der Wee N, Van Megen HJ, et al. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. Journal of Clinical Psychopharmacology. 2003 ; 23: 568-575 (Pubitemid 37443188)
28. De Veaugh-Geiss J, Landau P, Katz R. Treatment of obsessive compulsive disorder with clomipramine. Psychiatric Annals. 1989 ; 19: 97-101
29. De Veaugh-Geiss J, Moroz G, Biederman J, et al. Clomipramine hydrochloride in childhood and adolescent obsessive compulsive disorder: A multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry. 1992 ; 31: 45-49
30. Diniz JB, Shavitt RG, Pereira CA, et al. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: A randomized, open-label trial. Journal of Psychopharmacology. 2010 ; 24: 297-307
31. Dougherty DD, Jameson M, Deckersbach T, et al. Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. International Clinical Psychopharmacology. 2009 ; 24: 306-311
32. Drummond LM. The treatment of severe, chronic, resistant obsessive-compulsive disorder. An evaluation of an in-patient programme using behavioural psychotherapy in combination with other treatments. British Journal of Psychiatry. 1993 ; 163: 223-229 (Pubitemid 23233092)
33. Dunbar G, Steiner M, Bushnell WD, et al. Long-term treatment and prevention of relapse of obsessive compulsive disorder with paroxetine. European Neuropsychopharmacology. 1995 ; 5: 372
34. Englisch S, Esslinger C, Inta D, et al. Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. Clinical Neuropharmacology. 2009 ; 32: 227-229
35. Eser D, Baghai TC, Möller HJ. Agomelatine: The evidence for its place in the treatment of depression. Core Evidence. 2010 ; 4: 171-179
36. Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: A placebo-controlled study. Archives of General Psychiatry. 1998 ; 55: 918-924 (Pubitemid 28465782)
37. Farre JM, Fora F, Lasheras MG. Specific aspects of erectile dysfunction in psychiatry. International Journal of Impotence Research. 2004 ; 16: S46-49
38. Fernandez CE, Lopez-Ibor JJ. Monochlorimipramine in the treatment of psychiatric patients resistant to other therapies. Actas Luso-Españolas de Neurología, Psiquiatría y Ciencias Afines. 1967 ; 26: 119-147
39. Feusner JD, Kerwin L, Saxena S, et al. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: An open-label trial. Psychopharmacological Bulletin. 2009 ; 42: 81-93
40. Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. International Journal of Neuropsychopharmacology. 2005 ; 8: 107-129 (Pubitemid 40388819)
41. Fineberg NA, Chamberlain SR, Hollander E, et al. Translational approaches to obsessive-compulsive disorder: From animal models to clinical treatment. British Journal of Pharmacology. 2011 ; 164: 1044-1061
42. Fineberg N, Pampaloni I, Pallanti S, et al. Sustained response versus relapse: The pharmacotherapeutic goal for obsessive compulsive disorder. International Clinical Psychopharmacology. 2007a ; 22: 313-322 (Pubitemid 47530835)
43. Fineberg NA, Robbins TW, Bullmore E, et al. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: A narrative review. Neuropsychopharmacology. 2010 ; 35: 591-604
44. Fineberg NA, Sivakumaran T, Roberts A, et al. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: A randomized controlled treatment study. International Clinical Psychopharmacology. 2005 ; 20: 223-226 (Pubitemid 40896377)
45. Fineberg NA, Stein DJ, Premkumar P, et al. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A meta-analysis of randomized controlled treatment trials. International Clinical Psychopharmacology. 2006 ; 21: 337-343 (Pubitemid 44498275)
46. Fineberg NA, Tonnoir B, Lemming O, et al. Escitalopram prevents relapse of obsessive-compulsive disorder. European Neuropsychopharmacology. 2007b ; 17: 430-439 (Pubitemid 46497661)
47. Flament MF, Rapoport JL, Berg CJ, et al. Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Archives of General Psychiatry. 1985 ; 42: 977-983 (Pubitemid 15245091)
48. Foa EB, Steketee G, Kozak MJ, et al. Imipramine and placebo in the treatment of obsessive-compulsives: Their effect on depression and obsessional symptoms. Psychopharmacology Bulletin. 1987 ; 23: 8-11 (Pubitemid 17111653)
49. Freeman CPC, Trimble MR, Deakin JFW, et al. Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: A multicenter, randomized, double-blind parallel group comparison. Journal of Clinical Psychiatry. 1994 ; 55: 301-305 (Pubitemid 24265563)
50. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: A double-blind cross-over study. International Journal of Neuropsychopharmacology. 1999 ; 2: 193-195
51. Garcia AM, Sapyta JJ, Moore PS, et al. Predictors and moderators of treatment outcome in the Paediatric Obsessive Compulsive Treatment Study (POTS I). Journal of the American Academy of Child and Adolescent Psychiatry. 2010 ; 49: 1024-1033
52. Geller DA, Biederman J, Stewart SE, et al. Which SSRI? A meta-analysis of pharmacotherapy trials in paediatric obsessive-compulsive disorder. American Journal of Psychiatry. 2003a ; 160: 1919-1928 (Pubitemid 39619624)
53. Geller DA, Biederman J, Stewart SE, et al. Impact of co-morbidity on treatment response to paroxetine in paediatric obsessive compulsive disorder: Is the use of exclusion criteria empirically supported in randomised controlled trials?. Journal of Child and Adolescent Psychopharmacology. 2003b ; 13: S19-29
54. Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine Paediatric OCD Study Team. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2001 ; 40: 773-779 (Pubitemid 32595261)
55. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Archives of General Psychiatry. 1990 ; 47: 577-585 (Pubitemid 20189970)
56. Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: A multicentre, double-blind, placebo-controlled trial. International Clinical Psychopharmacology. 1996 ; 11: 21-29 (Pubitemid 26133288)
57. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Comparison of fluvoxamine and desipramine. Archives of General Psychiatry. 1989 ; 47: 577-585
58. Grady TA, Pigott TA, L'Heureux F, et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. American Journal of Psychiatry. 1993 ; 150: 819-821 (Pubitemid 23137694)
59. Grant P, Lougee L, Hirschtritt M, et al. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology. 2007 ; 17: 761-767 (Pubitemid 351158597)
60. Grant P, Song JY, Swedo SE. Review of the use of the glutamate antagonist riluzole in psychiatric disorders and a description of recent use in childhood obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology. 2010 ; 20: 309-315
61. Greenberg WM, Benedict MM, Doerfer J, et al. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. Journal of Psychiatric Research. 2009 ; 43: 664-670
62. Greist JH, Bandelow B, Hollander E, et al. Long-term treatment of obsessive-compulsive disorder in adults. CNS Spectrums. 2003 ; 8: 7-16 (Pubitemid 38419777)
63. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Archives of General Psychiatry. 1995a ; 52: 289-295
64. Greist JH, Jefferson JW, Kobak KA, et al. A one year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. International Clinical Psychopharmacology. 1995b ; 10: 57-65
65. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: A meta-analysis. Archives of General Psychiatry. 1995c ; 52: 53-60
66. Greist JH, Jefferson JW, Rosenfeld R, et al. Clomipramine and obsessive compulsive disorder: A placebo-controlled double-blind study of 32 patients. Journal of Clinical Psychiatry. 1990 ; 51: 292-297 (Pubitemid 20227021)
67. Harris E, Eng HY, Kowatch R, et al. Disinhibition as a side effect of treatment with fluvoxamine in paediatric patients with obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology. 2010 ; 20: 347-353
68. Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology. 1992 ; 12: 420-430
69. Hoehn-Saric R, Ninan P, Black DW, et al. Multicentre double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Archives of General Psychiatry. 2000 ; 57: 76-82 (Pubitemid 30035662)
70. Hollander E, Wong C. Psychosocial function and economic costs of obsessive compulsive disorder. CNS Spectrums. 1998 ; 3: 48-58.
71. Hollander E, Allen A, Steiner M, et al. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Journal of Clinical Psychiatry. 2003a ; 64: 1113-1121 (Pubitemid 37158259)
72. Hollander E, Kaplan A, Stahl SM. A double-blind placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World Journal of Biological Psychiatry. 2003b ; 4: 30-34
73. Hollander E, Koran LM, Goodman WK, et al. A double-blind placebo-controlled study of the efficacy and safety of controlled release fluvoxamine in patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry. 2003c ; 64: 640-647 (Pubitemid 36750140)
74. Hollander E, Rossi NB, Sood E, et al. Risperidone augmentation in treatment-resistant obsessive compulsive disorder: A double-blind, placebo controlled study. International Journal of Neuropsychopharmacology. 2003d ; 6: 397-401
75. Hollander E, Stein D, Fineberg NA, et al. Quality of life outcomes in patients with obsessive-compulsive disorder: Relationship to treatment response and symptom relapse. Journal of Clinical Psychiatry. 2010 ; 71: 784-792
76. Insel TR, Mueller EA, Alterman I, et al. Obsessive-compulsive disorder and serotonin: Is there a connection?. Biological Psychiatry. 1985 ; 20: 1174-1188 (Pubitemid 16053592)
77. Insel TR, Murphy DL, Cohen RM, et al. Obsessive-compulsive disorder - A double-blind trial of clomipramine and clorgyline. Archives of General Psychiatry. 1983 ; 40: 605-612 (Pubitemid 13094927)
78. Jenike MA, Baer L, Minichiello WE, et al. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. American Journal of Psychiatry. 1997 ; 154: 1261-1264 (Pubitemid 27369178)
79. Jenike MA, Baer L, Summergrad P, et al. Obsessive-compulsive disorder: A double-blind, placebo-controlled trial of clomipramine in 27 patients. American Journal of Psychiatry. 1989 ; 146: 1328-1330 (Pubitemid 19258485)
80. Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: Implications for a serotonergic theory. American Journal of Psychiatry. 1990 ; 147: 1209-1215 (Pubitemid 20275377)
81. Katz RJ, DeVeaugh-Geiss J, Landau P. Clomipramine in obsessive-compulsive disorder. Biological Psychiatry. 1990 ; 28: 401-404
82. Kim SW, Shin IS, Kim JM, et al. The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. Clinical Neuropharmacology. 2009 ; 32: 224-226
83. Kobak KA, Greist JH, Jefferson JW, et al. Behavioural versus pharmacological treatments of obsessive compulsive disorder: A meta-analysis. Psychopharmacology. 1998 ; 136: 205-216 (Pubitemid 28143169)
84. Koran LM, Gamel NN, Choung HW, et al. Mirtazapine for obsessive-compulsive disorder: An open trial followed by double-blind discontinuation. Journal of Clinical Psychiatry. 2005 ; 66: 515-520 (Pubitemid 40593581)
85. Koran LM, Hackett E, Rubin A, et al. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. American Journal of Psychiatry. 2002 ; 159: 89-95
86. KoranLMHannaGLHollanderE. (2007) Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA: American Psychiatric Association. Available at: www.psych.org/psych-pract/treatg/pg/prac-guide.cfm (accessed 19 November 2011).
87. Koran LM, McElroy SL, Davidson JR, et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison. Journal of Clinical Psychopharmacology. 1996 ; 16: 121-129 (Pubitemid 26142900)
88. Koran LM, Pallanti S, Querciolil L. Sumatriptan, 5-HT(1D) receptors and obsessive compulsive disorder. European Neuropsychopharmacology. 2001 ; 11: 169-172
89. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse-loading of clomipramine in obsessive compulsive disorder. American Journal of Psychiatry. 1997 ; 154: 396-401 (Pubitemid 27098291)
90. Kordon A, Wahl K, Koch N, et al. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: A double-blind, randomized, placebo-controlled study. Journal of Clinical Psychopharmacology. 2008 ; 28: 550-554
91. Kronig MH, Apter J, Asnis G, et al. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. Journal of Clinical Psychopharmacology. 1999 ; 19: 172-176 (Pubitemid 29161963)
92. Kumar S, Ng B, Howie W. The improvement of obsessive-compulsive symptoms in a patient with schizophrenia treated with clozapine. Psychiatry and Clinical Neurosciences. 2003 ; 57: 235-236 (Pubitemid 36505283)
93. Kushner MG, Kim SW, Donahue C, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry. 2007 ; 62: 835-838 (Pubitemid 47488217)
94. Lee KU, Lee YM, Nam JM, et al. Antidepressant-induced sexual dysfunction among newer antidepressants in a naturalistic setting. Psychiatry Investigation. 2010 ; 7: 55-59
95. Leonard HL, Swedo SE, Lenane MC, et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Archives of General Psychiatry. 1991 ; 48: 922-927
96. Leonard HL, Swedo S, Rapoport JL, et al. Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: A double-blind crossover comparison. Psychopharmacology Bulletin. 1988 ; 24: 93-95
97. Li X, May RS, Tolbert LC, et al. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: A crossover study. Journal of Clinical Psychiatry. 2005 ; 66: 736-743 (Pubitemid 40942420)
98. Liebowitz MR, Turner SM, Piacentini J, et al. Fluoxetine in children and adolescents with OCD: A placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2002 ; 41: 1431-1438 (Pubitemid 44698519)
99. Lopez-Ibor J, Saiz J, Cottraux J, et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. European Neuropsychopharmacology. 1996 ; 6: 111-118 (Pubitemid 26000424)
100. McDougle CJ, Walsh KH Obsessive Compulsive Disorder: A Practical Guide. Fineberg NA Marazitti D Stein D, ed. London: Martin Dunitz ; 2001: 135-152.
101. McDougle CJ, Barr LC, Goodman WK, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. American Journal of Psychiatry. 1995 ; 152: 1812-1814
102. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Archives of General Psychiatry. 2000 ; 57: 794-801 (Pubitemid 30650116)
103. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder. American Journal of Psychiatry. 1993 ; 150: 647-649 (Pubitemid 23109937)
104. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: A double-blind placebo-controlled study in patients with and without tics. Archives of General Psychiatry. 1994 ; 51: 302-308 (Pubitemid 24127303)
105. McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder. American Journal of Psychiatry. 1990 ; 147: 652-654 (Pubitemid 20153442)
106. McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: Lack of efficacy. Journal of Clinical Psychopharmacology. 1991 ; 11: 175-184
107. Maina G, Albert U, Ziero S, et al. Antipsychotic augmentation for treatment-resistant obsessive compulsive disorder: What if antipsychotic is discontinued?. International Clinical Psychopharmacology. 2003 ; 18: 23-28
108. Maina G, Pessina E, Albert U, et al. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. European Neuropsychopharmacology. 2008 ; 18: 364-372
109. Marazziti D, Pfanner C, Dell'Osso B, et al. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: An Italian long term open-label study. Journal of Psychopharmacology. 2005 ; 19: 392-394 (Pubitemid 41003135)
110. March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive compulsive disorder: A multicentre randomised controlled trial. Journal of the American Medical Association. 1998 ; 28: 1752-1756 (Pubitemid 28536875)
111. March JS, Frances A, Kahn DA, et al. The Expert Consensus Guideline series. Treatment of obsessive-compulsive disorder. Journal of Clinical Psychiatry. 1997 ; 58: 1-72
112. Marks IM, Lelliott P, Basoglu M, et al. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. British Journal of Psychiatry. 1988 ; 152: 522-534
113. Marks IM, Stern RS, Mawson D, et al. Clomipramine and exposure for obsessive-compulsive rituals. British Journal of Psychiatry. 1980 ; 136: 1-25
114. Matsunaga H, Nagata T, Hayashida K, et al. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry. 2009 ; 70: 863-868
115. Mavissakalian M, Turner SM, Michelson L, et al. Tricyclic antidepressants in obsessive-compulsive disorder: Antiobsessional or antidepressant agents? II. American Journal of Psychiatry. 1985 ; 142: 572-576 (Pubitemid 15034625)
116. Miguel EC, Diniz JB, Joaquim M, et al. Clomipramine and quetiapine augmentation for obsessive compulsive disorder compared with sustained fluoxetine treatment. American College of Neuropsychopharmacology, 49th Annual Meeting ; 2010 Miami Beach, Florida ; 2010..
117. Milanfranchi A, Ravagli S, Lensi P, et al. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive compulsive disorder. International Clinical Psychopharmacology. 1997 ; 12: 131-136 (Pubitemid 27283320)
118. Montgomery SA. Clomipramine in obsessional neurosis: A placebo-controlled trial. Pharmacological Medicine. 1980 ; 1: 189-192
119. Montgomery SA, Fineberg NA, Montgomery DB, et al. L-tryptophan in obsessive compulsive disorder: A placebo-controlled study. European Neuropsychopharmacology. 1992 ; 2: 384
120. Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20 mg, 40 mg, and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. International Clinical Psychopharmacology. 2001 ; 16: 75-86 (Pubitemid 32171832)
121. Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind placebo-controlled study of fluoxetine in patients with DSM-IIIR obsessive compulsive disorder. European Neuropsychopharmacology. 1993 ; 3: 143-152 (Pubitemid 24089504)
122. Mundo E, Bareggi SR, Pirola R, et al. Long-term pharmacotherapy of obsessive-compulsive disorder: A double-blind controlled study. Journal of Clinical Psychopharmacology. 1997a ; 17: 4-10 (Pubitemid 27047255)
123. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: A single-blind study. Journal of Clinical Psychopharmacology. 1997b ; 17: 267-271 (Pubitemid 27312424)
124. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: A double-blind, placebo-controlled study. International Clinical Psychopharmacology. 1998 ; 13: 219-224 (Pubitemid 28470313)
125. Mundo E, Rouillon F, Figuera ML, et al. Fluvoxamine in obsessive-compulsive disorder: Similar efficacy but superior tolerability in comparison with clomipramine. Human Psychopharmacology. 2001 ; 16: 461-468 (Pubitemid 32895589)
126. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology. 2011 ; 31: 174-179
127. NICE (2006) Obsessive-compulsive disorder: Core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. Available at: www.nice.org.uk/nicemedia/pdf/cg031fullguideline.pdf (accessed 19 November 2011).
128. Ninan PT, Koran LM, Kiev A, et al. High-dose sertraline strategy for non responders to acute treatment for obsessive-compulsive disorder: A multicenter double-blind trial. Journal of Clinical Psychiatry. 2006 ; 67: 15-22 (Pubitemid 43213277)
129. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Paediatric OCD Treatment Study (POTS) randomized controlled trial. Journal of American Medical Association. 2004 ; 292: 1969-1976
130. Pallanti S, Bernardi S, Antonini S, et al. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: A preliminary, single-blind, prospective study. CNS Drugs. 2009 ; 23: 1047-1055
131. Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without co morbid depression: A pilot study. Journal of Clinical Psychiatry. 2004 ; 65: 1394-1399
132. Pallanti S, Quercioli L, Koran LM. Citalopram infusions in resistant obsessive compulsive disorder: An open trial. Journal of Clinical Psychiatry. 2002 ; 63: 796-801
133. Pallanti S, Quercioli L, Paiva RS, et al. Citalopram for treatment-resistant obsessive-compulsive disorder. European Psychiatry. 1999 ; 14: 101-106
134. Pampaloni I, Sivakumaran T, Hawley CJ, et al. High-dose selective serotonin reuptake inhibitors in OCD: A systematic retrospective case notes survey. Journal of Psychopharmacology. 2010 ; 24: 1439-1445
135. Pasquini M, Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Progress in Neuro-psychopharmacology and Biological Psychiatry. 2006 ; 30 30: 1173-1175 (Pubitemid 43928231)
136. Pasquini M, Garavini A, Biondi M. Nicotine augmentation for refractory obsessive-compulsive disorder. A case report. Progress in Neuro- psychopharmacology and Biological Psychiatry. 2005 ; 29: 157-159 (Pubitemid 40018220)
137. Pato MT, Zohar-Kadouch R, Zohar J, et al. Return of symptoms after discontinuation of clomipramine in patients with obsessive compulsive disorder. American Journal of Psychiatry. 1988 ; 145: 1521-1525 (Pubitemid 19009698)
138. Pessina E, Albert U, Bogetto F, et al. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A 12-week open-label preliminary study. International Clinical Psychopharmacology. 2009 ; 24: 265-269
139. Piacentini J, Langley AK. Cognitive-behavioral therapy for children who have obsessive-compulsive disorder. Journal of Clinical Psychology. 2004 ; 60: 1181-1194 (Pubitemid 39392090)
140. Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive compulsive disorder. British Journal of Psychiatry. 1995 ; 166: 424-443
141. Pidrman V, Tuma I. Citalopram versus clomipramine in double-blind therapy of obsessive compulsive disorder. 11th Annual Meeting of the European College of Neuropsychopharmacology (ECNP) ; 1998 Paris, France ; 1998..
142. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive compulsive disorder. Journal of Clinical Psychiatry. 1999 ; 60: 101-106 (Pubitemid 29104386)
143. Pigott TA, L'Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive compulsive disorder. Journal of Clinical Psychopharmacology. 1992a ; 12: 11-18
144. Pigott TA, L'Heureux F, Rubinstein CF, et al. A controlled trial of clonazepam augmentation in OCD patients treated with clomipramine or fluoxetine. New Research Program and Abstracts of the 145th Annual Meeting of the American Psychiatric Association ; 1992b Washington, DC, USA ; 1992b..
145. Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive compulsive disorder. Behavioral and biological results. Archives of General Psychiatry. 1990 ; 47: 926-932 (Pubitemid 20348480)
146. Pigott TA, Pato MT, L'Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive compulsive disorder. Journal of Clinical Psychopharmacology. 1991 ; 11: 242-248
147. Pittenger C, Coric V, Banasr M, et al. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs. 2008 ; 22: 761-786
148. Rasmussen S, Hackett E, Duboff E, et al. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. International Clinical Psychopharmacology. 1997 ; 12: 309-316 (Pubitemid 28133228)
149. Ravizza L, Albert U, Ceregato A. Venlafaxine in obsessive compulsive disorder. Fifth International Obsessive Compulsive Disorder Conference ; 2001 Sardinia, Italy ; 2001..
150. Ravizza L, Maina G, Bogetto F, et al. Long term treatment of obsessive compulsive disorder. CNS Drugs. 1998 ; 10: 247-255 (Pubitemid 28516748)
151. Reddy YC, Alur AM, Manjunath S, et al. Long-term follow-up study of patients with serotonin reuptake inhibitor-nonresponsive obsessive-compulsive disorder. Journal of Clinical Psychopharmacology. 2010 ; 30: 267-272
152. Reynghe de, Voxrie GV. Anafranil (G34586) in obsessive neurosis. Acta Neurologica Belgica. 1968 ; 68: 787-792
153. Riddle MA, Reeve EA, Yaryura-Tobias J, et al. Fluvoxamine for children and adolescents with obsessive compulsive disorder: A randomised, controlled multicentre trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2001 ; 40: 222-229
154. Riddle MA, Scahill L, King RA, et al. Double-blind crossover trial of fluoxetine and placebo in children and adolescents with obsessive compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 1992 ; 31: 1062-1069
155. Robins LN, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Archives of General Psychiatry. 1984 ; 41: 949-958 (Pubitemid 14007854)
156. Romano S, Goodman WK, Tamura R, et al. Long-term treatment of obsessive-compulsive disorder after an acute response: A comparison of fluoxetine versus placebo. Journal of Clinical Psychopharmacology. 2001 ; 21: 46-52 (Pubitemid 32096749)
157. Rosenbaum JF, Fava M, Hoog S, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomised clinical trial. Biological Psychiatry. 1998 ; 44: 77-87 (Pubitemid 28305526)
158. Rouillon F. A double-blind comparison of fluvoxamine and clomipramine in OCD. European Neuropsychopharmacology. 1998 ; 8: 260-261
159. Sa AR, Hounie AG, Sampaio AS, et al. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Comprehensive Psychiatry. 2009 ; 50: 437-442
160. Savas H, Yumru M, Özen ME. Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder. Clinical Drug Investigation. 2008 ; 28: 439-442 (Pubitemid 351821481)
161. Scahill L, Riddle MA, McSwiggin-Hardin M, et al. Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry. 1997 ; 36: 844-852 (Pubitemid 27250450)
162. Shapira NA, Ward HE, Mandoki M, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biological Psychiatry. 2004 ; 55: 553-555 (Pubitemid 38338545)
163. Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: A meta-analysis of the randomized controlled trials. European Neuropsychopharmacology. 2007 ; 17: 79-93 (Pubitemid 44779187)
164. Skoog G, Skoog I. A 40 year follow up of patients with obsessive-compulsive disorder. Archives of General Psychiatry. 1999 ; 56: 121-127 (Pubitemid 29081385)
165. Smeraldi E, Ergovesi S, Bianchi I. Fluvoxamine versus clomipramine treatment in obsessive-compulsive disorder: A preliminary study. New Trends in Experimental and Clinical Psychiatry. 1992 ; 8: 63-65
166. Soltani F, Sayyah M, Feizy F, et al. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Human Psychopharmacology. 2010 ; 25: 509-513
167. Soomro GM, Altman D, Rajagopal S, et al. Selective serotonin reuptake inhibitors (SSRIs) versus placebo for obsessive-compulsive disorder (OCD). Cochrane Database Systematic Review. 2008 ; ( 1 ):
168. Stahl SM Stahl's Essential Psychopharmacology - Neuroscientific Basis and Practical Applications. Stahl SM, ed. Cambridge: Cambridge University Press ; 2008: 511-666.
169. Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials of obsessive compulsive disorder. International Clinical Psychopharmacology. 1995 ; 10: 11-18
170. Stein DJ, Tonnoir B, Andersen EW, et al. Escitalopram in OCD: A randomised, placebo-controlled, fixed-dose, paroxetine referenced, 24-week study. Current Medical Research Opinion. 2007 ; 23: 701-711
171. Stewart SE, Jenike AE, Hezel DM, et al. A single-blind case-control study of memantine in severe obsessive-compulsive disorder. Journal of Clinical Psychopharmacology. 2010 ; 30: 34-39
172. Storch EA, Merlo LJ, Bengtson M, et al. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology. 2008 ; 22: 230-237
173. Storch EA, Murphy TK, Goodman WK, et al. A preliminary study of D-cycloserine augmentation of cognitive behavioral therapy in paediatric obsessive compulsive disorder. Biological Psychiatry. 2010 ; 68: 1073-1076
174. Szegedi A, Wetzel H, Leal M, et al. Combination treatment with clomipramine and fluvoxamine: Drug monitoring, safety and tolerability data. Journal of Clinical Psychiatry. 1996 ; 57: 257-264 (Pubitemid 26230650)
175. Tenney NH, Denys DA, Van Megen HJGM, et al. Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorder. International Clinical Psychopharmacology. 2003 ; 18: 29-33 (Pubitemid 36127058)
176. Thoren P, Asberg M, Cronholm B, et al. Clomipramine treatment of obsessive compulsive disorder. Archives of General Psychiatry. 1980 ; 37: 1281-1285
177. Tollefson G, Rampey A, Potvin J, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry. 1994 ; 51: 559-567 (Pubitemid 24211033)
178. Ushijima S, Kamijima K, Asai M, et al. Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor, in the treatment of obsessive-compulsive disorder: A double blind placebo-controlled trial. Japanese Journal of Neuropsychopharmacology. 1997 ; 19: 603-623 (Pubitemid 27297321)
179. Uzun O. Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: A case report. Journal of Psychopharmacology. 2010 ; 24: 425-427
180. Van Ameringen M, Mancini C, Patterson B, et al. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: A retrospective, open label case series. Depression Anxiety. 2006 ; 23: 1-5
181. Vïsänen E, Ranta P, Nummikko-Pelkonen A, et al. Mianserin hydrochloride (Org GB 94) in the treatment of obsessional traits. Journal of International Medical Research. 1977 ; 5: 289-291 (Pubitemid 8145176)
182. Volavka J, Neziroglu F, Yaryura-Tobias JA. Clomipramine and imipramine in obsessive compulsive disorder. Psychiatry Research. 1985 ; 14: 85-93 (Pubitemid 15138646)
183. Vulink NC, Denys D, Fluitman SB, et al. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled study of 76 patients. Journal of Clinical Psychiatry. 2009 ; 70: 1001-1008
184. Wagner KD, March J, Landau P. Safety and efficacy of sertraline in long-term paediatric OCD treatment: A multicentre study. 39th Annual Meeting of the New Clinical Drug Evaluation Unit ; 1999 Boca Raton, FL, USA ; 1999..
185. Watson HJ, Rees CS. Meta-analysis of randomized, controlled treatment trials for paediatric obsessive-compulsive disorder. Journal of Child Psychology and Psychiatry. 2008 ; 49: 489-498 (Pubitemid 351503099)
186. Weissman MM, Bland RC, Canino GJ, et al. The cross national epidemiology of obsessive compulsive disorder. Journal of Clinical Psychiatry. 1994 ; 55: 5-10 (Pubitemid 24113069)
187. Wheadon D, Bushnell W, Steiner M. A fixed dose comparison of 20, 40 or 60 mg paroxetine to placebo in the treatment of obsessive compulsive disorder. 32nd Annual Meeting of the American College of Neuropsychopharmacology ; 1993 Honolulu, Hawaii, USA ; 1993..
188. Wilens TE, Biederman J, March J, et al. Absence of cardiovascular and adverse effects of sertraline in children and adolescents. Journal of American Academy of Child and Adolescent Psychiatry. 1999 ; 38: 573-577 (Pubitemid 29203473)
189. Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry. 2008 ; 165: 335-341 (Pubitemid 351704489)
190. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe - A critical review. European Neuropsychopharmacology. 2005 ; 15: 357-376 (Pubitemid 40943541)
191. Wood A, Tollefson GD, Burkitt M. Pharmacotherapy of obsessive compulsive disorder: Experience with fluoxetine. International Clinical Psychopharmacology. 1993 ; 8: 301-306 (Pubitemid 23301126)
192. World Health Organization (1999) The 'newly defined' burden of mental problems. Fact Sheet no. 217, Geneva: WHO ; 1999 :
193. Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessive compulsive disorder. Archives of General Psychiatry. 1996 ; 53: 653-654
194. Yaryura-Tobias JA, Neziroglu F, Bergman L. Clomipramine for obsessive-compulsive neurosis: An organic approach. Current Therapy Research. 1976 ; 20: 541-548
195. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive compulsive disorder. British Journal of Psychiatry. 1996 ; 169: 468-474